- Report
- September 2019
- 67 Pages
Global
From €4756EUR$4,950USD£4,083GBP
- Report
- March 2024
- 150 Pages
From €4987EUR$5,190USD£4,281GBP
- Report
- February 2023
- 217 Pages
Global
From €3060EUR$3,185USD£2,627GBP
€4372EUR$4,550USD£3,753GBP
- Report
- July 2022
- 100 Pages
Global
From €2642EUR$2,750USD£2,268GBP
- Report
- January 2022
- 70 Pages
Global
From €961EUR$1,000USD£825GBP
- Report
- January 2022
- 70 Pages
Global
From €961EUR$1,000USD£825GBP
- Report
- January 2022
- 90 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2022
- 150 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Report
- January 2022
- 70 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2022
- 125 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- January 2022
- 125 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- January 2022
- 90 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2022
- 90 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2022
- 125 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- April 2024
- 180 Pages
From €4708EUR$4,900USD£4,042GBP
- Report
- October 2023
- 81 Pages
Canada
From €3363EUR$3,500USD£2,887GBP
- Report
- March 2023
- 112 Pages
Global
From €4708EUR$4,900USD£4,042GBP
- Report
- January 2022
- 115 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Report
- January 2022
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Report
- January 2022
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
The Biosimilars and Biosuperiors market is a rapidly growing sector of the pharmaceutical industry. Biosimilars are biologic drugs that are highly similar to an existing biologic drug, while biosuperiors are biologic drugs that are more effective than an existing biologic drug. Biosimilars and biosuperiors are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases.
Biosimilars and biosuperiors are developed using advanced biotechnology techniques, such as recombinant DNA technology and monoclonal antibody technology. These drugs are designed to be more cost-effective than their original counterparts, while still providing the same therapeutic benefits.
The Biosimilars and Biosuperiors market is expected to continue to grow in the coming years, as more biologic drugs are developed and approved for use. Companies in this market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more